SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BRADLEY PHARMACEUTICALS (BPRXA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Brad Glassma3/25/1996 1:19:00 PM
   of 41
 
The strategy employed by BRADLEY PHARMACEUTICALS is the identical
one which MERCK used in the 1940's and 1950's. The reason the
large firm would sell is because it is not economically sound to
produce and market a little product when compared to a product like
CARDIZEM or PROCARDIA.

These huge companies produce and market huge products in very
strict economic terms. It is not as profitable to manufacture
100 of product x versus 1,000,000 units of product y.

In addition, little (a few million dollars) products are not economical
to market to a big firm. Often, these firms don't even advertise or
sample.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News